Allegan - AGN - Botox to feel good not just look good

While I was screening on Barchart for growth stocks having current upward price momentum  Allergan (AGN) came to the top of the lists.  As I read about the company I discovered that they market Botox not as an injective drug to reduce wrinkles but as a treatment for migraine headaches.  I guess if you've got wrinkles you are prone to headaches.  A shift of production facilities to Costa Rica may improve the bottom line.

Allergan, Inc. (AGN)  is also a provider of eye care and specialty pharmaceutical products throughout the world with products in the eye care pharmaceutical, ophthalmic surgical device, over-the-counter contact lens care, movement disorder, and dermatological markets. Its worldwide consolidated revenues are principally generated by prescription and non-prescription pharmaceutical products in the areas of ophthalmology and skin care, neurotoxins, intraocular lenses and other ophthalmic surgical products, and contact lens care products.

Technical Factors:

• 96% Barchart technical buy signals
• Trend Spotter buy signal
• 16 new highs and up 13.41% in the last month
• Relative Strength Index 77.80% and rising
• Trades around 79.24 with a 50 day moving average of 73.38

Fundamental Factors:

• 18 Wall Street brokerage firms are following this stock and look for double digit earnings growth
• Analysts have released 9 strong buy, 8 buy and 8 hold recommendations.  No negative reports have been released
• Sales are projected to increase by 7.00% this year and 8.20%  next year
• Earnings are estimated to increase by 14.20% this year, 15.80% next year and 14.63% annually for the next 5 years

General Investor Sentiment:

• There are 505 investors that have expressed an opinion on Motley Fool
• CAPS members vote 370 to 23 that the stock will beat the market
• The more experienced All Stars agree 127 to 5

At last we have a health care stock that isn't just hype.  This one has a solid following of both professional and individual investors with both expecting increases in sales and earnings.  

Put Allergan (AGN) on your watch lists.

Jim Van Meerten is an analyst for  Marketocracy Capital Management.  He shares his knowledge and experience from over 40 years of investing in stocks, mutual funds and ETFs on  Barchart.com  in his daily blog -- Barchart Portfolio Blogs.